ERBB2 and breast cancer: Rational design of GPER-targeted warheads for LYTACs or AbTAC-drug conjugates (ATDCs) holds promise for degrading membrane-bound GPER, blocking downstream signaling, and enabling intracellular delivery of conjugated drugs in the treatment of ER+/HER2− advanced BC patients.